A Look Back at an Extraordinary Year for Basic and Clinical Research on AIDS -- and the Questions Raised Additional Surprises Expected The year 1996 witnessed seismic developments in AIDS research. On many fronts -- the basic and the clinical,…
Effect of ddI on Ganciclovir May Explain Disparity Between Two Prophylaxis Studies And CMV PCR Makes its Debut Readers of TAGline are asked to harken back to the duelling ganciclovir studies unveiled this past winter (see the March TAGline, vol…
Flurry of Discoveries in Multiple Labs Leads to Identification of HIV's Second Receptor -- And New Therapeutic Target The Good, the Bad, the Ugly For nearly a decade Jay Levy, the crotchety virologist at the University of California in San…
At the IX International Conference on AIDS, the Treatment Action Group (TAG) debuted its recent treatment publication, The Wasting Report: Current Issues in the Treatment and Research of HIV-Associated Wasting and Malnutrition. Written by TAG's Tim Horn and David Pieribone,…
'Early' Is Right, They Say, Unless of Course Your Regimen's Wrong; Then You're Shit Out of Luck Burning Through Your Options One by One For this month's issue of TAGline, we decided to finish up last month's discussion with Aaron…
Smoldering Embers of HIV's 'Raging Fire,' Partly Doused, Threaten to Rekindle the Blaze A Thymus Trickles While we had the ear of Dr. David Ho, we thought we'd take advantage of the opportunity to sharpen our own picture of what…
The Fickle (and Unforgiving) Fashion of Antiretroviral Therapies: Early treatment choices and their unintended consequences. 'Early' AZT 1990 No survival benefit found; resistant mutant associated with more rapid progression. AZT+3TC 1994 Double resistance after one year; reduced sensitivity to other…
Something to Measure Propelled by Results From Multiple Studies, Viral Load Monitoring Lunges to the Forefront of HIV Medicine Optimization -- and Access -- Remain Recently, several very powerful and sensitive tests for measuring the presence of HIV RNA in…
The Latest Word on Protease Resistance A Turning Point Treatment Activists Sit Down with Vancouver High Fliers, Try to Make Sense Out of the New Cries of 'Eureka' Several weeks ago, at the July 15th TAG meeting, we met to…
Amino acid substitutions conferring reduced sensitivity to selected protease inhibitors: saquinavir (Invirase) 10 48 54 63 ritonavir (Norvir) 20 36 46 54 63 71 82 84 90 indinavir (Crixivan) 10 20 24 36 46 54 63 64 71 82 84…